marketing-medtech

**Country:** Austria (Vienna)
**Founder:** Moritz Schöllauf — Co-Founder & CEO (with Mario Zusag, Co-Founder & CTO; Dr. Philipp Schöllauf, Co-Founder & CSO)
**Background:** tech | verified: False — Legal / regulatory affairs, NOT tech. Moritz Schöllauf is a trained lawyer with a background in regulatory affairs (he attended the University of Vienna and worked in legal roles, including reportedly the European Parliament, before co-founding the company). He serves as Co-Founder and CEO. The "tech" background at nyra health belongs to a different co-founder, Mario Zusag (Co-Founder & CTO), a machine learning researcher previously at Google AI and IBM Research. The third co-founder, Dr. Philipp Schöllauf (CSO), is a medical doctor specialised in neurology.
**Stage / fundraise:** Series A / scale-up. Founded 2018 in Vienna (per company About page lineage and Crunchbase; candidate note's "2021" appears incorrect). Product live in 100+ neurological clinics, reimbursed by 28+ insurers — well past early stage. / €20M Series A closed Feb 2026, led by Armira Growth with Wellington Partners, Crane Venture Partners (managing MassMutual Ventures) and EVER Pharma; earlier ~€4.5M seed. Well-funded; raise already complete (not actively raising).
**Regulatory trigger:** Already holds MDR Class IIa CE certification for the myReha platform — i.e. the regulatory milestone is behind them, not ahead. Reimbursed by 28+ statutory/private German insurers and German Pension Insurance (DRV); ongoing MDR maintenance / technical-file upkeep is a steady-state obligation rather than an open trigger.
**Email:** info@nyra.health (confidence high) — info@nyra.health is the published general contact address on the company site (About/Contact pages). No published personal/founder address was found; firstname-based founder emails are NOT asserted to avoid fabrication. info@myreha.ai also appears as a legacy general address.
**LinkedIn:** Moritz Schöllauf: https://www.linkedin.com/in/moritz-sch%C3%B6llauf-53b4a4112/ ; Company: https://www.linkedin.com/company/nyrahealth/ **Website:** https://www.nyra.health
**Score:** 3 -> Tier C
**Hook:** Low-priority/adjacent fit. nyra already has the things OmDev sells (a strong ex-Google/IBM CTO, an in-house ML team, MDR Class IIa certification, and €20M of fresh capital to hire), so the standard "rent a senior team + dedicated CTO + MDR/IEC 62304 compliance engine at ~3x cheaper than in-house" pitch does not land. The only realistic angle is burst/overflow engineering capacity for the parallel US-entry, DACH-expansion and €4.2M AI research workstreams — but they are well-staffed to absorb these internally. Recommend deprioritize.

---

## Founder & background
nyra health GmbH (Vienna, founded 2018) was co-founded by **Moritz Schöllauf** (Mag., legal background — CEO), **Mario Zusag** (MSc Computing/ML, Imperial College London; ex-Google AI and IBM Research — CTO), and **Dr. Philipp Schöllauf** (neurologist from stroke rehab — CSO) ([About](https://www.nyra.health/en-us/ueber-uns); [Crunchbase](https://www.crunchbase.com/person/mario-zusag)).
This is the opposite of OmDev's ideal "non-technical founder, no CTO" profile: clinical depth, a serious ML CTO, and legal/regulatory competence are all in-house. No finance/insurance founder background found.

## Funding & momentum
Closed a **€20M Series A in Feb 2026**, led by Armira Growth, with Wellington Partners, Crane Venture Partners (managing MassMutual Ventures) and EVER Pharma; on top of an earlier ~€4.5M seed ([EU-Startups](https://www.eu-startups.com/2026/02/with-e65-billion-lost-each-year-to-stroke-and-dementia-in-germany-nyra-health-secures-e20-million-to-scale-digital-neurotherapy/); [Vestbee](https://www.vestbee.com/insights/articles/nyra-health-raises-20-m)).
Use of funds: US market entry with a pharma partner, DACH expansion, and a €4.2M AI research project with US universities. Well-funded and past the early stage — the round is already done, not open.

## Product & regulatory
**myReha** is AI-driven neurorehabilitation SaMD for speech/language/aphasia, cognition and fine-motor therapy after stroke, dementia and TBI, auto-adapting exercises from patient performance data ([myReha](https://www.nyra.health/en-us/myreha)).
Regulatory milestone is **behind them**: the platform is **MDR Class IIa certified**, live in 100+ clinics, and reimbursed by 28+ German insurers plus the German Pension Insurance ([LISAvienna](https://www.lisavienna.at/news/detail/ai-meets-neurology-nyra-health-receives-eur20-million-to-expand-into-the-leading-ai-platform-for-neurotherapy/)). Remaining work is steady-state MDR/IEC 62304 technical-file maintenance, not an open trigger.

## Pain & buying signals
Few of OmDev's buying signals are present: strong in-house CTO + ML team, in-house regulatory competence, MDR already certified, and €20M of fresh capital to hire directly. The only adjacent angle is burst/overflow engineering for the parallel US, DACH and AI-research workstreams — which they are well-positioned to staff internally.

**Why OmDev fits:** Honestly, weak fit. nyra already owns the team, the CTO, the certification and the cash that OmDev's model typically supplies, so the "senior team + dedicated CTO + MDR/IEC 62304 compliance engine, ~3x cheaper than in-house" value prop does not differentiate here. Best treated as overflow-capacity only and **deprioritized (Tier C)**. Published contact: info@nyra.health.

---
**Sources:** https://www.eu-startups.com/2026/02/with-e65-billion-lost-each-year-to-stroke-and-dementia-in-germany-nyra-health-secures-e20-million-to-scale-digital-neurotherapy/ · https://www.nyra.health/en-us/ueber-uns · https://www.crunchbase.com/person/mario-zusag · https://www.crunchbase.com/organization/myreha · https://www.vestbee.com/insights/articles/nyra-health-raises-20-m · https://www.lisavienna.at/news/detail/ai-meets-neurology-nyra-health-receives-eur20-million-to-expand-into-the-leading-ai-platform-for-neurotherapy/ · https://www.linkedin.com/in/moritz-sch%C3%B6llauf-53b4a4112/ · https://www.linkedin.com/company/nyrahealth/ · https://wellington-partners.com/nyra-seed-round/